Friday, 27 March 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 27 March 2026
News

PBAC fails the pub test on women

Posted 27 March 2026 AM

The PBAC has copped a spray from Perth-based Lawley pharmaceuticals, which is angry over the Committee's failure to give a recommendation to subsidise a testosterone cream for low libido in postmenopausal women.

Last November the PBAC withheld a recommendation for Lawley's AndroFeme 1, a one per cent testosterone topical cream that was listed on the ARTG in 2020 for the treatment of hypoactive sexual desire dysfunction (HSDD) in postmenopausal women, after a two-decade battle.

To see the whole article, please login

Popular

Company unveils role 'streamlining'
Why it's quitting time for pharma
Which pharmas are Most Ethical?
Pharma targets US$320B market
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home